Pharmaceuticals

A Swedish biotech and Belgian university secure major EU funding to advance a first-in-class drug against glioblastoma, a notoriously deadly brain tumor.

With a novel glutamate-targeting drug and a €38M cash injection, Newron aims to transform care for treatment-resistant schizophrenia.

The major CRO acquisition deepens Worldwide's oncology and FSP capabilities, signaling a strategic move in the consolidating clinical research market.

With no approved nonsurgical options for plantar fibromatosis, Keenova's new study and late-stage trial offer a significant glimmer of hope for sufferers.

A landmark trial shows Retevmo significantly cuts cancer recurrence in early-stage patients, pushing for a new standard of care and early genetic testing.

A landmark trial for Roche’s Gazyva shows unprecedented success in treating primary membranous nephropathy, offering hope of preventing kidney failure.

Nicox's novel glaucoma drug NCX 470 receives positive FDA feedback, keeping its 2026 U.S. market submission on track to challenge a $7B industry.

Disc Medicine's promising EPP drug hits a major roadblock as the FDA seeks more data, delaying hope for patients and setting up a high-stakes trial.

The firm reports a $195M cash reserve but a wider net loss as it nears crucial data readouts for its novel depression and anxiety drug candidates.

Iterum Therapeutics secures key Medicare access for its antibiotic ORLYNVAH™, but a costly FDA trial requirement for a new use casts a shadow on its future.

Alto Neuroscience completes enrollment for a trial of its skin patch drug, ALTO-101, offering new hope for the millions battling cognitive decline in schizophrenia.

STADA and Bio-Thera's new golimumab biosimilar wins European approval, promising to slash healthcare costs and expand treatment access for millions.

After its lead anxiety drug failed a key trial, Vistagen turns to AI and a new menopause treatment to secure its future. Can the company recover?

Appili Therapeutics lands a $40M deal to fight fungal threats, but with cash reserves low and loans due, can its science outpace its financial pressures?

Anebulo Pharmaceuticals is delisting from Nasdaq to focus on a pediatric cannabis antidote, leaving investors to grapple with an uncertain future.

With a promising heart failure drug in trials, the biotech aims to woo investors at the Oppenheimer conference to fund its attack on age-related diseases.

Celcuity adds Seagen commercial veteran Charles Romp to its board, a strategic move signaling its pivot from R&D to market readiness for gedatolisib.

In a landmark move, the FDA has removed major risk warnings from hormone therapy drugs, signaling a new era for women's health after decades of fear.

Dr. Ginna Laport, a leader from both pharma and academia, joins NMDP to spearhead a new initiative aimed at making life-saving cell therapies a reality for more patients.

With strong Phase 1 data and key FDA backing, Trethera's TRE-515 is advancing as a 'pipeline-in-a-product' for a wide range of diseases.